NCT06964191 - Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

November 15, 2026

Study Completion Date

November 15, 2026

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

COMBINATION_PRODUCT

PA5108 Ocular Implant low dose

The PA5108 Ocular Implant low dose is supplied preloaded into the needle of a single use administration device ready for use.

COMBINATION_PRODUCT

PA5108 Ocular Implant, high dose

The PA5108 Ocular Implant high dose is supplied preloaded into the needle of a single use administration device ready for use.

DRUG

Latanoprost 0.005% Ophthalmic Solution

Latanoprost eye drops at a concentration of 0.005%

Trial Locations (1)

RECRUITING

Eye Research Foundation, Newport Beach